TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8946439
Drug: Fluoxetine 40
Normalized name: fluoxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 40 mg plus dexfenfluramine 15 mg at night (Group II, n = 20)
Study: 1934527
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of GRF 1‐29 (0.3 micrograms/kg/h)
Study: 1934527
Drug: Clonidine pretreatment
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine pretreatment with GRF infusion
Study: 6285533
Drug: Standard immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard immunosuppressive therapy (antilymphoblast globulin, prednisone, and azathioprine)
Study: 22327574
Drug: Compound control
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound control (‐ve S. Enteritidis, +ve 0.75% TC or 1% EG)
Study: 22327574
Drug: Low-dose treatment
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose treatment (+ve S. Enteritidis, +ve 0.5% TC, or 0.75% EG)
Study: 22327574
Drug: High-dose treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose treatment (+ve S. Enteritidis, +ve 0.75% TC, or 1% EG)
Study: 10673878
Drug: Tropisetron 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 0.1 mg kg‐1 to a maximum of 5 mg
Study: 1918581
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 or 120 mg)
Study: 7249345
Drug: one puff
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: one puff in each nostril four times daily
Study: 7249345
Drug: two puffs
Approvals — FDA: no, EMA: no, PMDA: no
Description: two puffs in each nostril twice daily
Study: 25019571
Drug: Brivanib 800
Normalized name: Brivanib
DrugBank: Brivanib (DB11958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivanib 800 mg orally every day until disease progression or prohibitive toxicity
Study: 22110164
Drug: Both timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both timolol formulations
Study: 17537764
Drug: 1,200 mg
Normalized name: lecithin 1,200 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg weekly azithromycin
Study: 17537764
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg daily azithromycin (in patients aged <18 yrs)
Study: 17537764
Drug: 1,200 mg
Normalized name: lecithin 1,200 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg weekly azithromycin (in children)
Study: 11684377
Drug: Micronized progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized progesterone (P) 200 mg/day
Study: 8187108
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (NTG) - acute administration (2 days)
Study: 8187108
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (NTG) - continuous administration (24 days)
Study: 8187108
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (NTG) - intermittent administration (24 days)
Study: 27736248
Drug: Nitrate supplementation
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate supplementation (NIT) - 70 mL of beetroot juice containing 4 mmol NO3‐ for 8 days
Study: 21765964
Drug: Mass treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass treatment with anti-filarial drugs (4 annual administrations)
Study: 21765964
Drug: Mass treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass treatment with anti-filarial drugs in communities with high pre-treatment transmission (224-742 infective bites/person/year)
Study: 21765964
Drug: Mass treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass treatment with anti-filarial drugs in communities with moderate pre-treatment transmission (24-167 infective bites/person/year)
Study: 19478342
Drug: Protein supplement
Normalized name: PROTEIN SUPPLEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplement provided in the morning and evening (n = 13)
Study: 19478342
Drug: Protein supplement
Normalized name: PROTEIN SUPPLEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplement provided immediately before and immediately after workouts (n = 13)
Study: 19478342
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 7) with no protein or other nutritional supplement
Study: 12114886
Drug: Duloxetine 20
Normalized name: duloxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 20 mg/day
Study: 11282251
Drug: Clomipramine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 100 mg/day
Study: 9198080
Drug: Liquid non‐caloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid non‐caloric meal (5 mL water kg‐1)
Study: 4042306
Drug: naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: naloxone (10 mg iv followed by a continuous infusion of 10 mg/hr)
Study: 25636293
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control with oral hygiene instruction
Study: 18528294
Drug: Autologous tumor
Normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous tumor lysate-pulsed dendritic cell (DC) vaccine administered every other week for 3 doses
Study: 18528294
Drug: Autologous tumor
Normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous tumor lysate-pulsed DC vaccine followed by low-dose IL-2
Study: 18528294
Drug: Autologous tumor
Normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous tumor lysate-pulsed DC vaccine followed by high-dose IL-2
Study: 10690134
Drug: Rapacuronium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapacuronium 1.5 mg kg‐1 with three incremental doses of 0.5 mg kg‐1
Study: 10690134
Drug: Neostigmine vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine vs Edrophonium after three incremental doses of rapacuronium
Study: 3080114
Drug: Recombinant hepatitis
Normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hepatitis B vaccine derived from yeast
Study: 3080114
Drug: Plasma derived
Normalized name: c1-inhibitor, plasma derived
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma derived hepatitis B vaccine
Study: 30359369
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of social and physical stress
Study: 19761115
Drug: Spoon-needle cluster
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spoon-needle cluster (SNO) treatment
Study: 19761115
Drug: Filiform-needle cluster
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filiform-needle cluster (FNC) treatment
Study: 17174593
Drug: Control 1
Normalized name: Sebrx Acne Control 1 % Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control 1 (buccal smears prepared 1 week before the study)
Study: 17174593
Drug: Control 2
Normalized name: Appetite Control 200mcg-500mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control 2 (buccal smears at the start of the study before first exposure)
Study: 12241627
Drug: Clobetasone butyrate
Normalized name: clobetasone butyrate
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Clobetasone butyrate (CB) 0.05% cream
Study: 14522623
Drug: Hydrocortisone (HC)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HC) 1% cream
Study: 9273824
Drug: Control (other
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (other antihypertensive agents)
Study: 3578745
Drug: Balanced solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced solution of electrolytes and trace metals (Inzolen) with aspartate as the anion (group C)
Study: 27159758
Drug: Uterosacral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uterosacral suspension
Study: 27159758
Drug: Sacrospinous suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacrospinous suspension
Study: 24477778
Drug: Evolocumab 140
Normalized name: evolocumab 140 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 140 mg every 2 weeks or 420 mg every month
Study: 18427501
Drug: Sertraline (zofort)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (zofort) - selective serotonin reuptake inhibitor
Study: 16161725
Drug: Voucher-based contingency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voucher-based contingency management for substance abuse treatment (criminal justice involved)
Study: 16161725
Drug: Voucher-based contingency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voucher-based contingency management for substance abuse treatment (non-criminal justice involved)
Study: 11252342
Drug: Ceftazidime 6
Normalized name: ceftazidime 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 6 g/day by continuous infusion
Study: 11252342
Drug: Ceftazidime bolus
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime bolus dosing (2 g 8 hourly)
Study: 1835276
Drug: Aspirin (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (a nonspecific inhibitor of thromboxane synthesis)
Study: 1835276
Drug: Sulotroban (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulotroban (a specific thromboxane receptor antagonist)
Study: 31521942
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus VCAT‐J
Study: 26955982
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (TAU)
Study: 19129355
Drug: Deep transthecal
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep transthecal injection
Study: 19129355
Drug: Traditional transthecal
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional transthecal injection
Study: 15218710
Drug: Colgate Simply
Normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colgate Simply White Clear Whitening Gel, three times daily, 30-second air-drying and 30 minutes without eating/drinking
Study: 15218710
Drug: Colgate Simply
Normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colgate Simply White Clear Whitening Gel, four times daily, 30-second air-drying and 30 minutes without eating/drinking
Study: 15218710
Drug: Colgate Simply
Normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colgate Simply White Clear Whitening Gel, twice-daily, no air-drying, and 15 minutes without eating/drinking
Study: 9797080
Drug: G‐CSF 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF 5 microg/kg per day subcutaneously starting 2 days after S‐HAM treatment
Study: 2676877
Drug: Phenylpropanolamine (PPA)
DrugBank: Phenylpropanolamine (DB00397)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylpropanolamine (PPA) 37.5 mg immediate release
Study: 371318
Drug: 24 hours
Normalized name: PATCH, TRANSDERMAL 24 HOURS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 hours of preoperative antibiotic bowel preparation (gentamicin + vancomycin + mycostatin)
Study: 371318
Drug: 60 hours
Normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 hours of preoperative antibiotic bowel preparation (gentamicin + vancomycin + mycostatin)
Study: 27859427
Drug: Citrate HDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrate HDF (heparin free)
Study: 27859427
Drug: Acetate HDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetate HDF (routine dose of heparin)
Study: 26383152
Drug: SB742457 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB742457 (3 mg/d)
Study: 26383152
Drug: SB742457 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB742457 (15 mg/d)
Study: 26383152
Drug: SB742457 (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB742457 (35 mg/d)
Study: 26383152
Drug: SB742457 (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB742457 (3, 15, and 35 mg/d)
Study: 24136111
Drug: 8 h
Normalized name: Tylenol 8 Hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 h sitting interrupted with hourly, 8-min moderate-intensity cycling exercise bouts
Study: 16248986
Drug: Aprepitant 160
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant 160 mg
Study: 13679549
Drug: Combined diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined diltiazem and aspirin/ticlopidine therapy
Study: 13679549
Drug: Aspirin/ticlopidine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin/ticlopidine therapy alone
Study: 1420752
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg b.d. plus Pirenzepine 50 mg b.d.
Study: 1420752
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg b.d. plus Placebo (Control)
Study: 22649265
Drug: 140 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 g/d of lipid-based nutrient supplements (LNS)
Study: 22649265
Drug: No lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No lipid-based nutrient supplements (LNS)
Study: 15551388
Drug: Valerian 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian 300 mg
Study: 15551388
Drug: Valerian 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian 600 mg
Study: 11431240
Drug: Intramuscular olanzapine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular olanzapine, 10 mg
Study: 11431240
Drug: Intramuscular haloperidol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular haloperidol, 7.5 mg
Study: 7884790
Drug: Isradipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (5 mg to 15 mg once daily or 2.5 mg to 10 mg twice daily)
Study: 7884790
Drug: Isradipine with
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine with concomitant HCTZ (12.5 mg to 50 mg once daily)
Study: 30156056
Drug: Metformin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1,000 mg, twice daily)
Study: 30156056
Drug: Alogliptin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin (25 mg, once daily)
Study: 30268189
Drug: Group L
Normalized name: Blood group Lewis alpha-4-fucosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group L (surgical method L)
Study: 24200700
Drug: Group L
Normalized name: Blood group Lewis alpha-4-fucosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group L
Study: 27919638
Drug: Ezetimibe 10mg
Normalized name: EZETIMIBE 10MG TAB
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe 10mg + Atorvastatin 80mg
Study: 27919638
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Atorvastatin 80mg
Study: 26240491
Drug: Restriction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restriction of suspected foods and/or administration of ketotifen in the pEGE group (n=9)
Study: 17882913
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of cetirizine once per day
Study: 17882913
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of zafirlukast once per day
Study: 17882913
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of cafirlukast twice per day
Study: 17882913
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 20 mg of zafirlukast and 10 mg of cetirizine once per day
Study: 17882913
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 20 mg of zafirlukast twice per day and 10 mg cetirizine once per day
Study: 17882913
Drug: Low-dose anti-LT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose anti-LT
Study: 17882913
Drug: Antihistamine alone
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine alone
Study: 17882913
Drug: High-dose anti-LT
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose anti-LT or combination of low-dose anti-LT and antihistamine
Study: 15215154
Drug: High-dose intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intramuscular corticosteroids (triamcinolone)
Study: 11577957
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + AUG (amoxicillin/clavulanic acid 500 mg tid)
Study: 11577957
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + AUG (amoxicillin/clavulanic acid)
Study: 2600826
Drug: Nicotine polacrilex
Normalized name: Nicotine Polacrilex
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine polacrilex gum (2 or 4 mg)
Study: 2600826
Drug: Nicotine polacrilex
Normalized name: Nicotine Polacrilex
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine polacrilex (4 mg)
Study: 28284926
Drug: Dextrose infusion
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose infusion (0.9% saline control)
Study: 28284926
Drug: Acetylcholine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcholine infusion (both arms)
Study: 28284926
Drug: Dextrose infusion
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose infusion (after reperfusion)
Study: 24495641
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of a mixture of 65% nitrous oxide and oxygen during dressing change
Study: 24495641
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of oxygen during dressing change
Study: 21626011
Drug: Lidocaine concentration
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine concentration of 8 mg/mL
Study: 21626011
Drug: Lidocaine concentration
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine concentration of 5 mg/mL
Study: 21626011
Drug: Lidocaine concentration
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine concentration of 3.3 mg/mL
Study: 16515571
Drug: Epidoxorubicin 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidoxorubicin 120 mg/sqm for 4 months
Study: 8021765
Drug: Zidovudine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (60 to 180 mg/m2 per dose) given orally every 6 hours
Study: 8021765
Drug: Didanosine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine (60 to 180 mg/m2 per dose) given every 12 hours
Study: 8021765
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of zidovudine and didanosine
Study: 8021765
Drug: Zidovudine and
Normalized name: zidovudine and lamivudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine and didanosine after 4 and 12 weeks of treatment
Study: 810269
Drug: 2% solution
Normalized name: Lidomar 2% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% solution of sodium cromoglycate (SCG), administered as a fine spray six times a day for 4 weeks, approximately 31-32 mg daily.
Study: 810269
Drug: Placebo solution,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution, administered as a fine spray six times a day for 4 weeks.
Study: 29232379
Drug: sufentanil 0.1
Normalized name: bupivacaine-sufentanil 0.1%-1 mcg/mL-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: sufentanil 0.1 μg/kg (group S)
Study: 29232379
Drug: nalbuphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine 0.1 mg/kg (group N1)
Study: 29232379
Drug: nalbuphine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine 0.15 mg/kg (group N2)
Study: 29232379
Drug: nalbuphine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine 0.2 mg/kg (group N3)
Study: 26225794
Drug: 5α-reductase inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5α-reductase inhibitors (5αRIs) for 3 years after TURP
Study: 23072267
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus aromatherapy (rose essential oil)
Study: 23072267
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus placebo (physiological serum, 0.9% NaCl)
Study: 19801025
Drug: Bolus plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus plus bivalirudin infusion during and after PCI (4 hours, n = 88)
Study: 19801025
Drug: Bolus plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus plus bivalirudin infusion during PCI (n = 90)
Study: 16788335
Drug: Early access
Normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Early access to physical therapy treatment within 2 days (n=32)
Study: 1691882
Drug: Metoclopramide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (20 mg i.v.)
Study: 26923352
Drug: Steroid-sparing immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-sparing immunosuppressive regimens
Study: 26923352
Drug: JCPyV positive
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JCPyV positive donor IgG antibodies